Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Panacea BiotecBOM:531349 -3.33%54 Days Payable is 226.48 as of Mar. 2026, which is 17% below its 10-year median of 273.41. GuruFocus rates BOM:531349 with a GF Score™ of 54/100 and a GF Value™ of ₹360.38 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 702 Biotechnology companies, Panacea Biotec ranks better than 67.95% on this metric.
The historical rank and industry rank for Panacea Biotec's Days Payable or its related term are showing as below:
BOM:531349'
s Days Payable Range Over the Past 10 Years
Min: 5.54 Med: 273.41 Max: 492.38
Current: 260.55
During the past 13 years, Panacea Biotec's highest Days Payable was 492.38. The lowest was 5.54. And the median was 273.41.
BOM:531349's Days Payable is ranked better than 67.95% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs BOM:531349: 260.55
Panacea Biotec's Days Payable
declined
from Mar. 2025 (395.55) to Mar. 2026 (226.48).
It may suggest that Panacea Biotecaccelerated paying its suppliers.
Panacea Biotec Days Payable Related Terms
Panacea Biotec Days Payable Historical Data
* Premium members only.
The historical data trend for Panacea Biotec's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:531349 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Panacea Biotec's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panacea Biotec Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Panacea Biotec's Days Payable distribution charts can be found below:
* The bar in red indicates where Panacea Biotec's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Panacea Biotec's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panacea Biotec (BOM:531349) has a Days Payable of 226.48 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Panacea Biotec and its competitors. This is 17% below median its historical median of 273.41. Over the past decade, Panacea Biotec's Days Payable has ranged from 5.54 to 492.38. According to the industry distribution chart, Panacea Biotec ranks #225 out of 702 companies in the Biotechnology industry, placing it in the top 32.1%.
Is Panacea Biotec's Days Payable too high?
Panacea Biotec's current Days Payable of 226.48 is 17% below median its 10-year median of 273.41. Over the past 10 years, this metric has ranged from a low of 5.54 to a high of 492.38. The Biotechnology industry median Days Payable is 113.10. Panacea Biotec's value of 226.48 is 100.2% above this industry median. Based on the distribution chart, Panacea Biotec ranks #225 out of 702 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Panacea Biotec has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Panacea Biotec's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Panacea Biotec ranks #225 out of 702 companies for Days Payable. This puts Panacea Biotec in the upper half of its industry. The industry median Days Payable is 113.10. Panacea Biotec's value of 226.48 is 100.2% above this benchmark. Historically, Panacea Biotec's own Days Payable has ranged from 5.54 to 492.38 over the past decade. While the company's 10-year median is 273.41 vs. the industry median of 113.10, Panacea Biotec has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Panacea Biotec's current Days Payable of 226.48 is 100.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Panacea Biotec and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panacea Biotec's current Days Payable is 226.48, which is 17% below median its own 10-year median of 273.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Biotec stock overvalued right now?
Based on GuruFocus' analysis, Panacea Biotec (BOM:531349) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹360.38, compared to a current price of ₹548.40 — trading 52.2% above its estimated fair value. The current Days Payable is 226.48, which is 17% below median its 10-year median of 273.41 and 100.2% above the Biotechnology industry median of 113.10. Panacea Biotec's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Panacea Biotec (BOM:531349), the current Days Payable is 226.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Panacea Biotec (BOM:531349) Overvalued in 2026?
Based on GuruFocus' analysis, Panacea Biotec stock appears to be overvalued.
The current stock price of ₹548.40 is trading 52.2% above its estimated GF Value™ of ₹360.38.
GuruFocus considers Panacea Biotec to be Significantly Overvalued.
Key valuation signals for BOM:531349:
Days Payable: 226.48 (17% below median its 10-year median of 273.41)
GF Value™: ₹360.38 vs. price of ₹548.40 (52.2% above fair value)
Industry Position: 100.2% above the Biotechnology median (#225 of 702)
No single metric tells the full story. See the BOM:531349 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Panacea Biotec Ltd is a Biotechnology company. It is engaged in the business of research, development, manufacturing, and marketing of branded pharmaceutical formulations, vaccines, and biopharmaceuticals. The company's operating segments include Vaccines, and Formulations. It generates maximum revenue from the Vaccines segment. The company product portfolio includes prescription products in niche therapeutic areas such as diabetes and cardiovascular management, oncology, nephrology and transplant management, osteoporosis management, gastro-intestinal care, pain management products, and pediatric immunization. The group has a business presence in India and Outside India.
54GF Score
Get the complete analysis for BOM:531349
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531349 has been successfully added to your 
